[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-877-240-9479

Email address

information.center@astrazeneca.com

Condition

Diabetes Mellitus, Type 2,Skeletal Muscle Insulin Sensitivity

Treatment type

Interventional

Investigational product

Dapagliflozin

Phase

Phase 4

Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT03338855

Study number

D1690C00047

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to investigate the effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site